vs

Side-by-side financial comparison of Harmony Biosciences Holdings, Inc. (HRMY) and PicoCELA Inc. (PCLA). Click either name above to swap in a different company.

PicoCELA Inc. is the larger business by last-quarter revenue ($252.6M vs $243.8M, roughly 1.0× Harmony Biosciences Holdings, Inc.). Harmony Biosciences Holdings, Inc. runs the higher net margin — 9.2% vs -125.2%, a 134.4% gap on every dollar of revenue. Harmony Biosciences Holdings, Inc. produced more free cash flow last quarter ($126.0M vs $-256.6M).

Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological and central nervous system disorders. Its primary market is the United States, with its core product serving patients living with narcolepsy and other sleep-related CNS conditions across adult and pediatric segments.

PicoCELA Inc. is a global technology company specializing in low-power, high-reliability wireless connectivity solutions, including Wi-Fi HaLow modules and edge network infrastructure. It caters to industrial IoT, smart city, retail, and smart home segments, with a primary operational footprint across Asia, North America, and European markets.

HRMY vs PCLA — Head-to-Head

Bigger by revenue
PCLA
PCLA
1.0× larger
PCLA
$252.6M
$243.8M
HRMY
Higher net margin
HRMY
HRMY
134.4% more per $
HRMY
9.2%
-125.2%
PCLA
More free cash flow
HRMY
HRMY
$382.6M more FCF
HRMY
$126.0M
$-256.6M
PCLA

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
HRMY
HRMY
PCLA
PCLA
Revenue
$243.8M
$252.6M
Net Profit
$22.5M
$-316.2M
Gross Margin
71.9%
Operating Margin
15.8%
-114.8%
Net Margin
9.2%
-125.2%
Revenue YoY
21.1%
Net Profit YoY
-54.6%
EPS (diluted)
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HRMY
HRMY
PCLA
PCLA
Q4 25
$243.8M
Q3 25
$239.5M
Q2 25
$200.5M
Q1 25
$184.7M
$252.6M
Q4 24
$201.3M
Q3 24
$186.0M
Q2 24
$172.8M
Q1 24
$154.6M
Net Profit
HRMY
HRMY
PCLA
PCLA
Q4 25
$22.5M
Q3 25
$50.9M
Q2 25
$39.8M
Q1 25
$45.6M
$-316.2M
Q4 24
$49.5M
Q3 24
$46.1M
Q2 24
$11.6M
Q1 24
$38.3M
Gross Margin
HRMY
HRMY
PCLA
PCLA
Q4 25
71.9%
Q3 25
75.1%
Q2 25
81.0%
Q1 25
82.7%
Q4 24
73.0%
Q3 24
77.0%
Q2 24
81.4%
Q1 24
82.2%
Operating Margin
HRMY
HRMY
PCLA
PCLA
Q4 25
15.8%
Q3 25
27.3%
Q2 25
24.0%
Q1 25
30.4%
-114.8%
Q4 24
27.7%
Q3 24
33.2%
Q2 24
12.4%
Q1 24
33.7%
Net Margin
HRMY
HRMY
PCLA
PCLA
Q4 25
9.2%
Q3 25
21.2%
Q2 25
19.8%
Q1 25
24.7%
-125.2%
Q4 24
24.6%
Q3 24
24.8%
Q2 24
6.7%
Q1 24
24.8%
EPS (diluted)
HRMY
HRMY
PCLA
PCLA
Q4 25
$0.38
Q3 25
$0.87
Q2 25
$0.68
Q1 25
$0.78
Q4 24
$0.85
Q3 24
$0.79
Q2 24
$0.20
Q1 24
$0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HRMY
HRMY
PCLA
PCLA
Cash + ST InvestmentsLiquidity on hand
$775.3M
$456.8M
Total DebtLower is stronger
$163.7M
Stockholders' EquityBook value
$870.2M
$354.8M
Total Assets
$1.3B
$1.2B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HRMY
HRMY
PCLA
PCLA
Q4 25
$775.3M
Q3 25
$672.6M
Q2 25
$565.3M
Q1 25
$507.0M
$456.8M
Q4 24
$467.2M
Q3 24
$410.5M
Q2 24
$346.9M
Q1 24
$372.4M
Total Debt
HRMY
HRMY
PCLA
PCLA
Q4 25
$163.7M
Q3 25
$168.5M
Q2 25
$172.1M
Q1 25
$175.7M
Q4 24
$179.3M
Q3 24
$182.8M
Q2 24
$186.4M
Q1 24
$190.0M
Stockholders' Equity
HRMY
HRMY
PCLA
PCLA
Q4 25
$870.2M
Q3 25
$835.1M
Q2 25
$773.1M
Q1 25
$720.5M
$354.8M
Q4 24
$659.2M
Q3 24
$596.8M
Q2 24
$538.6M
Q1 24
$515.4M
Total Assets
HRMY
HRMY
PCLA
PCLA
Q4 25
$1.3B
Q3 25
$1.2B
Q2 25
$1.1B
Q1 25
$1.1B
$1.2B
Q4 24
$999.2M
Q3 24
$928.1M
Q2 24
$858.4M
Q1 24
$847.0M
Debt / Equity
HRMY
HRMY
PCLA
PCLA
Q4 25
0.19×
Q3 25
0.20×
Q2 25
0.22×
Q1 25
0.24×
Q4 24
0.27×
Q3 24
0.31×
Q2 24
0.35×
Q1 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HRMY
HRMY
PCLA
PCLA
Operating Cash FlowLast quarter
$126.2M
$-245.6M
Free Cash FlowOCF − Capex
$126.0M
$-256.6M
FCF MarginFCF / Revenue
51.7%
-101.6%
Capex IntensityCapex / Revenue
0.0%
4.3%
Cash ConversionOCF / Net Profit
5.61×
TTM Free Cash FlowTrailing 4 quarters
$347.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HRMY
HRMY
PCLA
PCLA
Q4 25
$126.2M
Q3 25
$108.7M
Q2 25
$79.3M
Q1 25
$34.0M
$-245.6M
Q4 24
$75.6M
Q3 24
$70.5M
Q2 24
$42.6M
Q1 24
$31.1M
Free Cash Flow
HRMY
HRMY
PCLA
PCLA
Q4 25
$126.0M
Q3 25
$108.7M
Q2 25
$79.3M
Q1 25
$33.9M
$-256.6M
Q4 24
$75.0M
Q3 24
$70.5M
Q2 24
$42.0M
Q1 24
$31.1M
FCF Margin
HRMY
HRMY
PCLA
PCLA
Q4 25
51.7%
Q3 25
45.4%
Q2 25
39.6%
Q1 25
18.3%
-101.6%
Q4 24
37.3%
Q3 24
37.9%
Q2 24
24.3%
Q1 24
20.1%
Capex Intensity
HRMY
HRMY
PCLA
PCLA
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
4.3%
Q4 24
0.3%
Q3 24
0.0%
Q2 24
0.4%
Q1 24
0.0%
Cash Conversion
HRMY
HRMY
PCLA
PCLA
Q4 25
5.61×
Q3 25
2.14×
Q2 25
1.99×
Q1 25
0.75×
Q4 24
1.53×
Q3 24
1.53×
Q2 24
3.68×
Q1 24
0.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HRMY
HRMY

Segment breakdown not available.

PCLA
PCLA

Revenue from product$179.1M71%
Revenue from SaaS, Maintenance and others$42.4M17%
Revenue from product – related party$31.0M12%

Related Comparisons